FRCs are not advised for patients lacking insulin secretion (proved by serum C-peptide level), advanced renal impairment (eGFR < 30 mL/min), pregnancy or breastfeeding, a history of pancreatitis, or known hypersensitivity to any components of these therapies [49]. This evidence concerns the gene INS and pancreatitis.